“ald518” Archives

in
Entry Author Date Location
Bristol-Myers, Alder Drug for Rheumatoid Arthritis Passes Key Test 10/28/13 Seattle
Alder Gets $3.5M Milestone as Bristol-Myers Starts Crohn’s Study 08/27/12 Seattle
Alder Biopharma Snags $38M To Charge Ahead With Antibody Drugs 04/19/12 Seattle
Allozyne’s Backdoor IPO, Sound Pharma Fights iPod Deafness, Mirina Vs. Marina Ends, & More Seattle-Area Life Sciences News 06/23/11 Seattle
Alder Gets $15M From Bristol 06/20/11 Seattle
Alder Steers Next Antibodies To Unusual Places: Treating Migraines and High Cholesterol 03/02/11 Seattle
Alder Reduces Anemia in Cancer Study 06/06/10 Seattle
Alder’s Long-Awaited Arthritis Data, Ikaria Plots $200M IPO, Emerald’s Resurrection, & More Seattle-Area Life Sciences News 05/20/10 Seattle
Alder, Bristol Arthritis Drug Shows “Outstanding” Results in Trial, Lead Researcher Says 05/17/10 Seattle
Alder Seeks to Treat Cancer in a Radical Way, Fighting Inflammation, Not Tumors 05/13/10 Seattle
Alder Rises From Ashes of Layoffs to Become Seattle Biotech Force 01/04/10 Seattle
Alder and New Partner, Bristol, to Give Amgen and Abbott a Run for Their Money 11/11/09 Seattle
Alder Scores Deal With Bristol-Myers Potentially Worth $1 Billion 11/10/09 Seattle
Alder Expands Partnership with Schering-Plough, Adds “Significant” Upfront Cash 06/08/09 Seattle
Alder Drug Fights Cancer Fatigue 06/01/09 Seattle
ASCO Preview: Seattle Genetics, ZymoGenetics, Trubion & Other Seattle Biotechs Offer Peeks at Cancer Drug Results 05/15/09 Seattle
Alder Gets Early Christmas Present: FDA Slaps Down Its Rival, Roche 12/08/08 Seattle
Alder Sets Stage for Showdown With Roche, With “Fast Follower” Antibody Drug Strategy 09/18/08 Seattle
Page 1 of 1